The term curcuminoids encompasses three active compounds: curcumin, demethoxycurcumin, and bisdemethoxycurcumin
In 2023, an estimated 13.3 million Medicare beneficiaries enrolled in Parts A and B had obesity or overweight, based on having BMI of 27 or more recorded in claims or encounter data, or 24% of Medicare beneficiaries overall (Figure 1)
The next couple pathways we will sorta combine together as they are both metabolism coded, the PI3K/AkT/mTOR and AMPK pathways
The safest conclusion is simple: treat patch claims as unverified until proven, because most consumer patches do not provide enough reliable data to confirm a medication level mechanism, and large peptides do not cross intact skin the way the ads imply
lean mass (body composition data pending) Cardiovascular outcomes (TRIUMPH-Outcomes trial ongoing, results expected 2027-2028) How it performs in the general obesity population without osteoarthritis (TRIUMPH-1 results pending) Optimal maintenance dose (4mg maintenance is being studied) Real-world effectiveness outside controlled trial conditions Retatrutide vs
%25201.png)
